The US Food and Drug Administration issued a notice on the 9th saying that the use of glucagon-like peptide-1 receptor agonists may increase the risk of developing a rare eye disease that may cause permanent vision loss, and that all marketing application holders of related drugs are required to add risk warning information to drug instructions. The drugs involved include simeglutide, liraglutide, and tirpotide.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.